Summit Trail Advisors LLC Reduces Stock Holdings in Humana Inc. (NYSE:HUM)

Summit Trail Advisors LLC trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 11.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,289 shares of the insurance provider’s stock after selling 160 shares during the period. Summit Trail Advisors LLC’s holdings in Humana were worth $410,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. grew its stake in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Creative Financial Designs Inc. ADV grew its stake in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. purchased a new position in Humana during the 3rd quarter worth $29,000. Hantz Financial Services Inc. purchased a new position in Humana during the 2nd quarter worth $35,000. Finally, Family Firm Inc. purchased a new position in Humana during the 2nd quarter worth $37,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HUM has been the topic of several research analyst reports. KeyCorp initiated coverage on Humana in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company dropped their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Barclays boosted their price target on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $315.86.

Humana Stock Performance

Shares of HUM stock opened at $295.49 on Wednesday. The company has a market capitalization of $35.58 billion, a P/E ratio of 26.17, a P/E/G ratio of 2.35 and a beta of 0.52. The business’s 50 day moving average is $276.28 and its two-hundred day moving average is $330.23. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Analysts expect that Humana Inc. will post 15.86 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.20%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.